• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

Precedent: volatile market will change - in time

Q. I am very concerned about the stock market, and I am consideringselling all of my holdings. Does it make sense to sell now before the marketgoes much lower?

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!
Related Videos
Related Content
Upadacitinib Induces Long-Term Remission in Refractory Bullous Pemphigoid: A Case Report
June 19th 2025

Upadacitinib Induces Long-Term Remission in Refractory Bullous Pemphigoid: A Case Report

Derm Dispatch: Advocating for Skin and Nail Health to Spread Melanoma Awareness
May 23rd 2025

Derm Dispatch: Advocating for Skin and Nail Health to Spread Melanoma Awareness

Social Media Significantly Influences Attitudes, Behaviors Toward Skin Health
June 19th 2025

Social Media Significantly Influences Attitudes, Behaviors Toward Skin Health

Derm Dispatch: Discussing Early Detection and Education With a Melanoma Survivor
May 20th 2025

Derm Dispatch: Discussing Early Detection and Education With a Melanoma Survivor

Daily Derm Times: June 18, 2025
June 19th 2025

Daily Derm Times: June 18, 2025

Both Upadacitinib and Abrocitinib Demonstrate Real-World Efficacy in AD Patients After 1 Year
June 18th 2025

Both Upadacitinib and Abrocitinib Demonstrate Real-World Efficacy in AD Patients After 1 Year

© 2025 MJH Life Sciences

All rights reserved.